Evidence map›Paper›PMID 41924431›Full record

ArticleF1000Research2025

Prognostic Role of Absolute Monocyte Count, CD163⁺ Macrophages, and CD8⁺ Lymphocytes in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.

Faisal Syarifuddin, Anna Mira Lubis, Agnes Stephanie Harahap, Hamzah Shatri, Wulyo Rajabto, Imam Subekti, Rudy Hidayat, Sukamto Koesnoe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Faisal SyarifuddinDivision of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, 10430, Indonesia.ORCID https://orcid.org/0009-0008-8366-6364
Anna Mira LubisDivision of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, 10430, Indonesia.ORCID https://orcid.org/0000-0003-4961-1737
Agnes Stephanie HarahapDepartment of Pathological Anatomy, Faculty of Medicine, Universitas Indonesia, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, 10430, Indonesia.
Hamzah ShatriDivision of Psychosomatic and Palliative Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, 10430, Indonesia.ORCID https://orcid.org/0000-0003-1393-9669
Wulyo RajabtoDivision of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, 10430, Indonesia.
Imam SubektiDivision of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, 10430, Indonesia.
Rudy HidayatDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, 10430, Indonesia.
Sukamto KoesnoeDivision of Allergy Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, 10430, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) exhibits heterogeneous clinical outcomes, including variations in event-free survival (EFS). Tumor microenvironment (TME) components, particularly absolute monocyte count (AMC), tumor-associated macrophages (TAMs), and tumor-infiltrating lymphocytes (TILs) have been implicated in prognosis, although findings remain inconsistent. This study evaluates the prognostic value of AMC, TAMs (CD163), and TILs (CD8) on two-year EFS in DLBCL patients treated with R-CHOP. Methods: A retrospective cohort study of 108 DLBCL patients treated from January 2014 to March 2021 was conducted. AMC was obtained from peripheral blood, while CD163 and CD8 expressions were analyzed via immunohistochemistry. Associations with two-year EFS were assessed using hazard ratios (HR), and correlations between AMC and tissue immune markers were evaluated. Results: High AMC and CD163 expression were significantly associated with poorer two-year EFS (HR = 9.82 and 8.57; both p < 0.001), whereas elevated CD8 expression predicted better outcomes (HR = 0.13; p < 0.001). AMC positively correlated with CD163 (r = 0.577; p < 0.001) and negatively with CD8 (r = -0.599; p < 0.001). Conclusion: AMC and CD163 are negative prognostic markers, while CD8 is protective. AMC may reflect the immune profile of the TME and serve as a practical prognostic biomarker in DLBCL.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticAntineoplastic Combined Chemotherapy ProtocolsCD8-Positive T-LymphocytesLymphoma, Large B-Cell, DiffuseMacrophagesMonocytesReceptors, Cell SurfaceAdultAgedCD163 AntigenCyclophosphamideDoxorubicinFemaleHumansLeukocyte CountAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolReceptors, Cell SurfaceRituximabVincristineCD163CD8DLBCLmonocyte countprognosistumor microenvironment

Identifiers

PMID41924431
PMCPMC13036440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.